Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

NCT04208347 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

580

Enrollment

OTHER

Sponsor class

Conditions

Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions

DRUG: Apatinib 250mg
DRUG: Camrelizumab
DRUG: S-1, Oxaliplatin
DRUG: Apatinib 500mg

Sponsor

Ruijin Hospital